The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Drugs and Valvular Heart Disease
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, valvular heart disease is associated with anorectic agents, such as fenfluramine, and antimigraine medications, such as ergot-amine, via serotonin 5-HT2B receptor agonism66.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [66]
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 52
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citation
Cited by
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
“Serotonin also plays a pathological role in the cardiac valvulopathy caused by the appetite suppressant fenfluramine (see sidebar, Serotonergic Drugs andValvular Heart Disease) (7, 34).”
InfluentialSelf-citationPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
“Comparison of the predicted Bayesian and observed polypharmacology profiles for (1) donepezil (compound 1); (2) the isoindole analogues (compounds 2–8)—of the 160 ligand– target associations, 100 were correctly predicted by the Bayesian models (P 5 0.”
BackgroundSelf-citationReducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Urban, D. J., & Roth, B. L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124803 · Cited by 668
Self-citationHow Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
“The most infamous example is likely the anti-obesity drug fenfluramine, which was withdrawn because of association with valvular heart disease in many individuals (Allen and Roth, 2011; Roth, 2007).”
BackgroundSelf-citationFidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Structural Basis for Molecular Recognition at Serotonin Receptors
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X.-P., Vardy, E., et al. (2013) · Science · doi:10.1126/science.1232807 · Cited by 528
“However, clinical use of several serotonergic drugs caused unexpected side effects arising from off-target interactions with 5-HT receptor subtypes and related receptors for biogenic amine (1, 4, 8, 9).”
BackgroundSelf-citationStructure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone
Wang, S., Che, T., Levit, A., Shoichet, B. K., Wacker, D., & Roth, B. L. (2018) · Nature · doi:10.1038/nature25758 · Cited by 483
Self-citationVan Voorhis, W. C., Adams, J. H., Adelfio, R., Ahyong, V., Akabas, M. H., Alano, P., Alday, A., Alemán Resto, Y., Alsibaee, A., Alzualde, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005763 · Cited by 435
“One of the most severe GPCR-related adverse effects is cardiac valvulopathy linked to 5-HT2B activation [11, 12].”
Schoen, F. J. (2008) · Circulation · doi:10.1161/circulationaha.108.805911 · Cited by 421
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133348 · Cited by 402
“…of agonist activity at human 5-HT2A or 5-HT2B receptors include cardiac valvular disease (Connolly et al., 1997; Devereux, 1998; Fitzgerald et al., 2000; Rothman et al., 2000; Horowski et al., 2004; Roth, 2007) and possibly pulmonary hypertension (Abenhaim et al., 1996; Launay et al., 2002).”
BackgroundInfluentialUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Self-citationSerotonin and Blood Pressure Regulation
Watts, S. W., Morrison, S. F., Davis, R. P., & Barman, S. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004697 · Cited by 396
“Significant interest has been paid to the expression of 5-HT receptors on aortic valves (especially the 5-HT 2B receptor), because the 5-HT releaser and weight-loss drug fenfluramine causes valvular dysfunction (Roth, 2007; Huang et al., 2009; Hajjo et al., 2010).”
BackgroundStructure and function of serotonin G protein-coupled receptors
McCorvy, J. D., & Roth, B. L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.009 · Cited by 372
“Ultimately with continued use, severe chronic side-effects can occur such as retroperitoneal fibrosis, pleuropulmonary fibrosis, and cardiac valvulopathy due to off-target activity at the 5-HT2B receptor (Roth, 2007; Rothman et al., 2000), which will be discussed in the next section.”
Self-citationLaverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Jensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301646 · Cited by 316
“For example, drug-induced valvular heart disease is frequently due to the 5-HT2B receptor agonism of metabolites (Roth, 2007; Rothman et al, 2000), while the M1 muscarinic receptor activation by the metabolite desmethylclozapine may contribute to the clinical efficacy of the antipsychotic drug clozapine (Davies et al,…”
BackgroundMethodInfluentialSelf-citationErratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Self-citationThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Self-citationAmisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
“Agonists at the 5-HT2B receptor have been associated with cardiac valvulopathy (Rothman et al. 2000; Roth 2007; Berger et al. 2009), while 5-HT2B antagonists such as amisulpride (Huang et al.”
Self-citationGiacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., & Nakamura, Y. (2007) · Nature · doi:10.1038/446975a · Cited by 276
Platelet-derived serotonin links vascular disease and tissue fibrosis
Dees, C., Akhmetshina, A., Zerr, P., Reich, N., Palumbo, K., Horn, A., Jüngel, A., Beyer, C., Krönke, G., Zwerina, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101629 · Cited by 266
“has been implicated in the development of fibrotic changes by selected ergots such as pergolide or bromocriptine, anorexins like fenfluramine, or drugs of abuse as for example MDMA (3,4-methylenedioxymethamphetamine; also known as ecstasy; Rothman et al., 2000; Setola et al., 2003; Hofmann et al., 2006; Roth, 2007).”
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
“The activation of 5-HT2B receptors in cardiovascular tissues may potentially result in cardiac valvulopathy and is thus a concern for drugs that increase plasma 5-HT levels or directly activate 5-HT2B receptors (Elangbam 2010; Elangbam et al. 2008; Huang et al. 2009; Roth 2007).”
BackgroundBarnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationThe evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Engineering GPCR signaling pathways with RASSLs
Conklin, B. R., Hsiao, E. C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J. R., Guettier, J.-M., Chang, W. C., Pei, Y., McCarthy, K. D., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1232 · Cited by 254
“For instance, drug-induced valvular heart disease may be caused by excessive stimulation of cardiac 5-HT 2B receptor”
BackgroundSelf-citationSerotonin receptors and heart valve disease—It was meant 2B
Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.008 · Cited by 252
“…the NIMH Psychoactive Drug Screening Program has sought to screen large numbers of FDA-approved drugs and drug-like compounds for agonist activity at 5-HT2B receptors in order to identify drugs/chemotypes with HVD liability (Setola, Dukat et al. 2005; Roth 2007; Huang, Setola et al. 2009).”
BackgroundMethodInfluentialSelf-citationBespoke library docking for 5-HT2A receptor agonists with antidepressant activity
Kaplan, A. L., Confair, D. N., Kim, K., Barros-Álvarez, X., Rodriguiz, R. M., Yang, Y., Kweon, O. S., Che, T., McCorvy, J. D., Kamber, D. N., et al. (2022) · Nature · doi:10.1038/s41586-022-05258-z · Cited by 245
Self-citation5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology
Peng, Y., McCorvy, J. D., Harpsøe, K., Lansu, K., Yuan, S., Popov, P., Qu, L., Pu, M., Che, T., Nikolajsen, L. F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.001 · Cited by 247
“Creating selective 5-HT2C agonists is extremely challenging, however, as off-target agonist activity at the closely related 5-HT2A and 5-HT2B receptors leads to lysergic acid diethylamide (LSD)-like hallucinations (Nichols, 2016) and cardiac valvulopathy (Roth, 2007), respectively.”
Self-citationKlibanski, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0912025 · Cited by 236
The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
Chanson, P., & Maiter, D. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101290 · Cited by 237
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
Antonini, A., & Poewe, W. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70218-1 · Cited by 231
Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors
Modlin, I. M., Moss, S. F., Chung, D. C., Jensen, R. T., & Snyderwine, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn275 · Cited by 224
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Self-citationWeight Loss Strategies for Treatment of Obesity
Kushner, R. F. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2013.09.005 · Cited by 219
“induced valvulopathy seen from two other serotonergic agents previously removed from the market, fenfluramine and dexfenflurame, was due to activation of the 5-HT2B receptors expressed on cardiac valvular interstitial cells.(42) By activation of the 5-HT2C receptor, lorcaserin is thought to decrease food intake throug…”
BackgroundAortic valve disease and treatment: The need for naturally engineered solutions
Butcher, J. T., Mahler, G. J., & Hockaday, L. A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.01.008 · Cited by 210
“These include weight loss drugs (fenfluramine and dexfenfluramine); drugs used to treat migraine headaches (ergot alkaloids, ergotamine, and methysergide); ergot-derived dopaminergic compounds used for Parkinson's disease, restless legs syndrome, and hyperprolactinemic disorders (pergolide and cabergoline); and the am…”
BackgroundProlactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0236 · Cited by 209
5-HT2B receptors are required for serotonin-selective antidepressant actions
Diaz, S. L., Doly, S., Narboux-Nême, N., Fernández, S., Mazot, P., Banas, S. M., Boutourlinsky, K., Moutkine, I., Belmer, A., Roumier, A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.159 · Cited by 200
Monoamine transporter and receptor interaction profiles of a new series of designer cathinones
Simmler, L. D., Rickli, A., Hoener, M. C., & Liechti, M. E. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.008 · Cited by 200
“5-HT2B receptors have been implicated in drug-associated cardiac valve fibrosis (Roth, 2007) and the behavioral effects of MDMA (Doly et al.”
BackgroundThe promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Self-citationThe serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
Antonini, A., Tolosa, E., Mizuno, Y., Yamamoto, M., & Poewe, W. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70225-x · Cited by 193
Delgrange, E., Daems, T., Verhelst, J., Abs, R., & Maiter, D. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0012 · Cited by 194
Lorcaserin (APD356), a Selective 5‐HT2CAgonist, Reduces Body Weight in Obese Men and Women
Smith, S. R., Prosser, W. A., Donahue, D. J., Morgan, M. E., Anderson, C. M., Shanahan, W. R., & APD356‐004 Study Group (2009) · Obesity · doi:10.1038/oby.2008.537 · Cited by 192
“Agonist activity at the 5-HT2B receptor is a common feature of drugs associated with valvulopathy (28).”
BackgroundAnti-obesity drugs: a review about their effects and their safety
Derosa, G., & Maffioli, P. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.675326 · Cited by 185
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 184
Self-citationNeurochemical profiles of some novel psychoactive substances
Iversen, L., Gibbons, S., Treble, R., Setola, V., Huang, X.-P., & Roth, B. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.006 · Cited by 175
Self-citationStructural determinants of 5-HT2B receptor activation and biased agonism
McCorvy, J. D., Wacker, D., Wang, S., Agegnehu, B., Liu, J., Lansu, K., Tribo, A. R., Olsen, R. H. J., Che, T., Jin, J., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0116-7 · Cited by 171
Self-citationCarcinoid Heart Disease: From Pathophysiology to Treatment - ‘Something in the Way It Moves'
Grozinsky-Glasberg, S., Grossman, A. B., & Gross, D. J. (2015) · Neuroendocrinology · doi:10.1159/000381930 · Cited by 171
Management of medically refractory prolactinoma
Molitch, M. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1270-8 · Cited by 165
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD
Cao, C., Barros-Álvarez, X., Zhang, S., Kim, K., Dämgen, M. A., Panova, O., Suomivuori, C.-M., Fay, J. F., Zhong, X., Krumm, B. E., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.08.006 · Cited by 159
Self-citationBorovac, J. A. (2016) · PubMed Central · Cited by 239
Role of Parafacial Nuclei in Control of Breathing in Adult Rats
Huckstepp, R. T. R., Cardoza, K. P., Henderson, L. E., & Feldman, J. L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2953-14.2015 · Cited by 162
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 152
“Thus, we predicted that MDMA and pergolide use might be associated with VHD—predictions that were validated in 2007 (Droogmans et al., 2007; Roth, 2007; Schade et al., 2007; Zanettini et al., 2007).”
BackgroundInfluentialSelf-citationDrug-induced fibrotic valvular heart disease
Bhattacharyya, S., Schapira, A. H. V., Mikhailidis, D. P., & Davar, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60252-x · Cited by 147
Pharmacology of stimulants prohibited by the World Anti‐Doping Agency (WADA)
Docherty, J. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.124 · Cited by 149
“This is an anti-obesity agent withdrawn in the United States in 1997 due to cardiac-valve abnormalities (30% of users may have abnormal valves) and pulmonary hypertension; both effects are linked to serotoninomimetic actions and valvular actions may involve 5HT2B-receptor activation (Roth, 2007).”
BackgroundDirected molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Dong, S., Rogan, S. C., & Roth, B. L. (2010) · Nature Protocols · doi:10.1038/nprot.2009.239 · Cited by 156
Self-citationGustafsson, B. I., Hauso, Ø., Drozdov, I. A., Kidd, M. S., & Modlin, I. M. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.02.019 · Cited by 148
Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus
Weill, A., Païta, M., Tuppin, P., Fagot, J., Neumann, A., Simon, D., Ricordeau, P., Montastruc, J., & Allemand, H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2044 · Cited by 151
Serotonergic drugs and valvular heart disease
Rothman, R. B., & Baumann, M. H. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902931524 · Cited by 144
“These predictions have been borne out by subsequent clinical investigations [18,79].”
BackgroundResultInfluentialDopamine Receptors and Parkinson's Disease
Hisahara, S., & Shimohama, S. (2011) · International Journal of Medicinal Chemistry · doi:10.1155/2011/403039 · Cited by 182
Recommandations françaises de prise en charge de la drépanocytose de l'adulte : actualisation 2015
Habibi, A., Arlet, J. B., Stankovic, K., Gellen‐Dautremer, J., Ribeil, J., Bartolucci, P., & Lionnet, F. (2015) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(15)60002-9 · Cited by 149
Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy
Kushner, R. F. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.06.001 · Cited by 163
Martin, C. K., Redman, L. M., Zhang, J., Sanchez, M., Anderson, C. M., Smith, S. R., & Ravussin, É. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1848 · Cited by 135
“heart valve disease and hypertension) (7, 8) activation.”
BackgroundDrug-induced Valvulopathy: An Update
Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 146
“However, only 5-HT2BR has been implicated in valvulopathy because of its high concentration in human heart valves and pulmonary arteries (Fitzgerald et al. 2000; Rothman et al. 2000; Roth 2007).”
BackgroundInfluentialPotential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia
Valassi, E., Klibanski, A., & Biller, B. M. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2095 · Cited by 129
“Stimulation of the 5HT2B receptor causes excessive proliferation of fibromyoblasts, leading to a valvulopathy (17).”
BackgroundCabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti, P., Livadariu, E., Марков, М. Б., Daly, A., Burlacu, M., Betea, D., Piérard, L., & Beckers, A. M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0213 · Cited by 119
“When stimulated, it promotes mitogenesis and proliferation of fibroblasts, resulting in an overgrowth valvulopathy (3, 4 ). In Parkinson’s disease, the severity of cardiac valve regurgitation is directly related to the cumulative exposure to (duration and dose) cabergoline and pergolide (5–8).”
BackgroundBehlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 135
Welch, J. T., & Lim, D. S. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.012 · Cited by 118
Pharmacological profile of novel psychoactive benzofurans
Rickli, A., Kopf, S., Hoener, M. C., & Liechti, M. E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13128 · Cited by 128
“The 5-HT2A receptor mediates hallucinogenic effects (Nichols, 2004), and the 5-HT2B receptor has been implicated in drug-associated endocardial fibrosis (Roth, 2007).”
BackgroundCunningham, K. A., Fox, R. G., Anastasio, N. C., Bubar, M. J., Stutz, S. J., Moeller, F. G., Gilbertson, S. R., & Rosenzweig-Lipson, S. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.034 · Cited by 112
“Furthermore, as 5-HT2AR or 5- HT2BR agonists would be expected to evoke hallucinations (Nichols, 2004) or cardiac valvulopathy (Fitzgerald, et al., 2000; Roth, 2007), respectively, therapeutically-useful 5- HT2CR agonists must not have demonstrable efficacy at 5-HT2AR or 5-HT2BR in vivo.”
BackgroundElangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L., Gates, L. D., & Slocum, N. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.03.005 · Cited by 110
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
Meltzer, H. Y., & Roth, B. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70678 · Cited by 123
“As discussed below, 5-HT2B receptors are enriched in the heart (27), and drugs likely mediate their valvulopathogenic actions on heart valves via a combination of G protein and β-arrestin signaling (27–29).”
Self-citationLi, B., Zhang, S., Zhang, H., Nu, W., Cai, L., Hertz, L., & Peng, L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1306-5 · Cited by 109
“Moreover, activation 5-HT2B receptors is of clinical relevance for valvular heart disease, since a number of compounds activating these receptors cause mitogenesis in cultured valve cells and induce valvular heart disease in the clinic, and the only reason therapeutically relevant concentrations of fluoxetine do not h…”
BackgroundGPCR crystal structures: Medicinal chemistry in the pocket
Shonberg, J., Kling, R. C., Gmeiner, P., & Löber, S. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.034 · Cited by 136
Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse
Berridge, B. R., Mowat, V., Nagai, H., Nyska, A., Okazaki, Y., Clements, P., Rinke, M., Snyder, P. W., Boyle, M. C., & Wells, M. Y. (2016) · Journal of Toxicologic Pathology · doi:10.1293/tox.29.3s-1 · Cited by 118
“…patients taking the anti-Parkinsonian drugs pergolide and cabergoline (ergot-derived drugs with po- tent 5HT2B receptor activity) or with serotonin-secreting carcinoid tumors (Bratter et al. 1999; Cosyns et al. 2013; Droogmans et al. 2007; Elangbam et al. 2008; Gustafsson et al. 2005; Roth 2007).”
BackgroundInvestigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 109
Prophylaxis of migraine: general principles and patient acceptance
D’Amico, D., Tepper, S. J., & D’Amico, D. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3497 · Cited by 110
“Dr Tepper: grants/research support from Allergan, Alexza, ANS/Advanced Bionics, AstraZeneca, Eisai, Endo, Forrest, GSK, King, Merck, Medtronix, Minster, Neurochem, NMT, Novartis, Nupathe, OrthoMcNeil, Pfizer, Pozen, Proethic, Takeda, Winston, Vernalis.”
InfluentialVilar, L., Abucham, J., Albuquerque, J. L., de Araújo, L. A., Azevedo, M. F., Boguszewski, C. L., Casulari, L. A., Cunha, M. B. C., Czepielewski, M. A., Duarte, F. H. G., et al. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000032 · Cited by 110
“The underlying mechanism involves the activation of the 5-hydroxytryptamine 2B (5-HT2B) receptors, abundantly expressed on heart valves, which induces a cascade of events involving mitogenesis, fibroblast proliferation, valve thickening and, finally, valvular dysfunction (141,142).”
BackgroundPituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
Babey, M. E., Sahli, R. G., Vajtai, I., Andres, R. H., & Seiler, R. W. (2010) · Pituitary · doi:10.1007/s11102-010-0283-y · Cited by 102
“The stimulation of 5-HT2B receptors, which is known to activate several mitogenic pathways, appears to be a key step in initiating cabergoline-or pergolide induced valvular heart disease in patients with PD [44].”
BackgroundNeuroendocrine tumors and fibrosis: An unsolved mystery?
Laskaratos, F., Rombouts, K., Caplin, M. E., Toumpanakis, C., Thirlwell, C., & Mandair, D. (2017) · Cancer · doi:10.1002/cncr.31079 · Cited by 101
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults
Giustina, A., Barkan, A. L., Chanson, P., Grossman, A. B., Hoffman, A. R., Ghigo, E., Casanueva, F. F., Colao, A., Lamberts, S. W. J., Sheppard, M., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03349263 · Cited by 100
DREADDs: novel tools for drug discovery and development
Lee, H.-M., Giguère, P. M., & Roth, B. L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.018 · Cited by 103
“, cabergoline and pergolide [34]) and some ergot derivatives [4,11].”
BackgroundSelf-citationBenfluorex and Unexplained Valvular Heart Disease: A Case-Control Study
Frachon, I., ETIENNE, Y., Jobic, Y., Gal, G. L., Humbert, M. J. C., & Leroyer, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010128 · Cited by 95
“Consequently, practitioners were warned of the possible side effects of potent 5-HT2B receptor agonists [3,18].”
BackgroundPalacios, J. M., Pazos, Á., & Hoyer, D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4545-5 · Cited by 101
“Obviously, their 5-HT2BR agonism represented a major and dramatic ‘side’ effect and led to their discontinuation and that of other 5-HT2BR agonists (Roth 2007).”
BackgroundRoth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.654764 · Cited by 88
“pergolide, cabergoline, and dihydroergotamine), we correctly predicted that these medications would also induce valvular heart disease (7, 8).”
BackgroundSelf-citationActivity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors
León, F., Obeng, S., Mottinelli, M., Chen, Y., King, T. I., Berthold, E. C., Kamble, S. H., Restrepo, L. F., Patel, A., Gamez-Jimenez, L. R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00726 · Cited by 88
Mechanisms of Function and Disease of Natural and Replacement Heart Valves
Schöen, F. J. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130257 · Cited by 93
“and methysergide or ergotamine therapy for migraine headaches (108) are associated with valvular heart disease in some patients.”
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 100
“Some 5-HT2B agonists are associated with valvular heart disease (Roth, 2007; Rothman et al., 2000).”
BackgroundConn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 90
Self-citationLopez-Munoz, F. J., & Álamo, C. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00102 · Cited by 100
“It is well-known that drugs that stimulate that particular receptor are closely tied to acute heart valve disease (61).”
BackgroundCan we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 87
Key Characteristics of Cardiovascular Toxicants
Lind, L., Araujo, J. A., Barchowsky, A., Belcher, S. M., Berridge, B. R., Chiamvimonvat, N., Chiu, W. A., Cogliano, V. J., Elmore, S., Farraj, A. K., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp9321 · Cited by 91
“…of 5-HT2B receptors; dose-dependent valve leaflet fibroplasia and thickening in mice, rats, and humans; development of valvular cardiac disease in clinical studies (Elangbam et al. 2008; Elangbam 2010; Fitzgerald et al. 2000; Reid et al. 2013; Roth 2007; Rothman et al. 2000; Taylor et al. 2007).”
BackgroundSerotonin receptors in epilepsy: Novel treatment targets?
Sourbron, J., & Lagae, L. G. (2022) · Epilepsia Open · doi:10.1002/epi4.12580 · Cited by 84
Gómez, R., Abad, A., Delgado, F., Tamarit, S., Simón, C., & Pellicer, A. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.10.024 · Cited by 82
Delgado-Rosas, F., Gómez, R., Ferrero, H., Gaytán, F., García-Velasco, J. A., Simón, C., & Pellicer, A. (2011) · Reproduction · doi:10.1530/rep-11-0223 · Cited by 79
“Unlike Cb2, quinagolide is unlikely to affect cardiac valve tissue and, www.reproduction-online.org therefore, is not expected to induce proliferation of fibroblasts (Roth 2007) or regurgitation.”
Background
Metadata
- Authors
- Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Roth, Bryan L.
- ORCID
- Roth, Bryan L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 6-9
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965258805
- Cited by
- 479
- References
- 7
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 30 · 2015: 29 · 2014: 25 · 2013: 32 · 2012: 28
- FWCI
- 35.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- fenfluramine, dexfenfluramine, valvular heart disease, drug-induced valvular disease, leaflet thickening, echocardiographic findings
- MeSH terms
- Cabergoline, Antiparkinson Agents, Ergolines, Heart Valve Diseases, Humans, Pergolide, Serotonin Receptor Agonists, Dopamine Agonists, Receptor, Serotonin, 5-HT2B, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.